Fig. 4From: Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cellsUSP7 inhibitor decreased H2Bub1 in USP22+/+ cells and further enhanced p53 activation in USP22-Kd cancer cells. A. Impact of FT671 treatment on H2Bub1 in the parental and USP22-Kd HCT116 cancer cells. B. Western blot analysis of Sirt1-P53-P21 in the parental (USP22+/+) and USP22-Ko (USP22-/-) A549 cells treated with FT671Back to article page